Atria Wealth Solutions Inc. Sells 3,248 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Atria Wealth Solutions Inc. lowered its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 15.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,318 shares of the medical equipment provider’s stock after selling 3,248 shares during the period. Atria Wealth Solutions Inc.’s holdings in Zimmer Biomet were worth $2,111,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in ZBH. GAMMA Investing LLC acquired a new stake in shares of Zimmer Biomet during the fourth quarter worth $65,000. Community Bank & Trust Waco Texas boosted its holdings in Zimmer Biomet by 60.6% in the 4th quarter. Community Bank & Trust Waco Texas now owns 5,736 shares of the medical equipment provider’s stock valued at $698,000 after purchasing an additional 2,164 shares during the period. Wedge Capital Management L L P NC grew its position in shares of Zimmer Biomet by 3.3% during the 4th quarter. Wedge Capital Management L L P NC now owns 123,822 shares of the medical equipment provider’s stock worth $15,069,000 after purchasing an additional 4,000 shares in the last quarter. RWA Wealth Partners LLC bought a new position in shares of Zimmer Biomet during the fourth quarter worth approximately $375,000. Finally, Sumitomo Mitsui DS Asset Management Company Ltd raised its position in shares of Zimmer Biomet by 1.9% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 18,859 shares of the medical equipment provider’s stock valued at $2,295,000 after buying an additional 344 shares in the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Zimmer Biomet

In related news, VP Chad F. Phipps sold 26,156 shares of the business’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the transaction, the vice president now owns 44,145 shares in the company, valued at $5,677,929.90. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.70% of the stock is currently owned by corporate insiders.

Zimmer Biomet Price Performance

ZBH stock opened at $121.70 on Tuesday. The company has a market capitalization of $25.00 billion, a P/E ratio of 24.89, a PEG ratio of 2.19 and a beta of 1.01. The company has a fifty day moving average price of $125.92 and a 200-day moving average price of $119.80. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.78 and a current ratio of 1.61. Zimmer Biomet Holdings, Inc. has a 52-week low of $102.00 and a 52-week high of $149.25.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.15 by $0.05. The business had revenue of $1.94 billion during the quarter, compared to analyst estimates of $1.93 billion. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. Zimmer Biomet’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same period last year, the company earned $1.88 EPS. As a group, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.07 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date of this dividend is Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio is currently 19.63%.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Canaccord Genuity Group reissued a “hold” rating and set a $130.00 price target on shares of Zimmer Biomet in a research report on Friday, February 23rd. JPMorgan Chase & Co. increased their price objective on shares of Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a research note on Friday, February 9th. Raymond James boosted their target price on shares of Zimmer Biomet from $133.00 to $137.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. Barclays increased their price target on shares of Zimmer Biomet from $120.00 to $130.00 and gave the stock an “underweight” rating in a research report on Monday, February 12th. Finally, StockNews.com downgraded shares of Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a research report on Monday, February 19th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $139.39.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.